SCHEMBL30342705

SCHEMBL30342705

CCN(CC)Cc1ccc(N=Cc2cc(Cl)ccc2O)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 10/20 0.60
▸ CA12 O43570 2/20 0.55
▸ CA2 P00918 2/20 0.55
▸ CA9 Q16790 2/20 0.55
▸ MAOB P27338 1/20 0.55
▸ LMNA P02545 3/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ MAPT P10636 6/20 0.53
▸ KMT2A Q03164 5/20 0.53
▸ MEN1 O00255 4/20 0.50
▸ KDM4E B2RXH2 3/20 0.50
▸ GAA P10253 3/20 0.50
▸ THRB P10828 3/20 0.50
▸ MAPK1 P28482 2/20 0.50
▸ RAB9A P51151 1/20 0.47
▸ HSD17B10 Q99714 2/20 0.45
▸ CYP2D6 P10635 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ CASP1 P29466 2/20 0.45
▸ CASP7 P55210 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31502238 0.87 MAPT (0.47) ALDH1A1CA12CA2CA9MAOB
SCHEMBL31502131 0.84 ALDH1A1 (0.70) ALDH1A1CA12CA2CA9MAOB
SCHEMBL30342922 0.84 ALDH1A1 (0.70) ALDH1A1CA12CA2CA9MAOB
SCHEMBL30342590 0.81 ALDH1A1 (0.81) ALDH1A1CA12CA2CA9MAOB
SCHEMBL11407791 0.81 ALDH1A1 (0.81) ALDH1A1CA12CA2CA9MAOB
SCHEMBL11407794 0.81 ALDH1A1 (0.81) ALDH1A1CA12CA2CA9MAOB
SCHEMBL13639899 0.81 ALDH1A1 (0.67) ALDH1A1CA12CA2CA9MAOB
SCHEMBL12858528 0.77 LMNA (0.66) ALDH1A1CA12CA2CA9MAOB
SCHEMBL17507455 0.77 ALDH1A1 (0.62) ALDH1A1CA12CA2CA9MAOB
SCHEMBL30342555 0.77 KMT2A (0.39) ALDH1A1CA12CA2CA9MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129015-A1 HALOGENATED BENZYLIDINE DERIVATIVES Renovel Innovations, Inc. (US) 2025-04-24 — — US claimed
US-20230107812-A1 HALOGENATED BENZYLIDINE DERIVATIVES Renovel Innovations, Inc. 2023-04-06 — — US claimed
US-20250129015-A1 HALOGENATED BENZYLIDINE DERIVATIVES Renovel Innovations, Inc. (US) 2025-04-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129015-A1 HALOGENATED BENZYLIDINE DERIVATIVES BRD2, MPO, BRD9 ALDH1A1 1995/4885CA12 3439/4885CA2 3987/4885
US-20230107812-A1 HALOGENATED BENZYLIDINE DERIVATIVES BRD2, MPO, BRD9 ALDH1A1 1995/4885CA12 3439/4885CA2 3987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback